Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163776 | 0.83 | MAP2K1 (0.53) | LTA4HTDP1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL1768943 | 0.82 | MAP2K1 (0.52) | LTA4HTDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2231076 | 0.82 | SLC6A2 (0.57) | LTA4HTDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24180195 | 0.82 | PARP15 (0.55) | LTA4HDRD2DRD4 | |
| SCHEMBL1475391 | 0.81 | TDP1 (0.68) | LTA4HTDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21618371 | 0.81 | TDP1 (0.49) | LTA4HTDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2296643 | 0.81 | TDP1 (0.67) | TDP1SLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL15301000 | 0.81 | TDP1 (0.45) | LTA4HTDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14312078 | 0.80 | MAOB (0.46) | TDP1SLC6A2SLC6A4SLC6A3DRD4 | |
| SCHEMBL21618381 | 0.80 | LTA4H (0.50) | LTA4HTDP1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | LTA4H 1226/4885TDP1 2812/4885SLC6A2 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.